Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.025
-0.025 (-1.22%)
At close: Oct 9, 2026, 4:00 PM EDT
1.986
-0.039 (-1.91%)
After-hours: Oct 9, 2026, 5:22 PM EDT

Aytu BioPharma Financials Overview

Millions USD. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Revenue
57.5757.5766.3865.1873.896.67
Revenue Growth
-13.28%-13.28%1.84%-11.68%-23.66%47.29%
Gross Profit
36.8236.8245.8349.0552.2350.28
Operating Income
-8.32-8.322.540.57-5.21-38.1
Net Income
-14.25-14.25-13.56-15.84-17.05-108.78
Earnings Per Share
-1.16-1.16-2.16-2.86-5.11-74.01
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Cash & Investments
26.3126.3130.9520.0122.9919.36
Total Debt
18.1118.1122.9416.4218.4518.19
Net Cash (Debt)
8.28.28.023.594.531.17
Net Cash Growth
2.33%2.33%123.38%-20.87%286.86%-95.29%
Net Cash Per Share
0.670.671.280.651.360.80

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Cash Flow
3.283.28-1.94-1.39-5.13-28.82
Capital Expenditures
-0.03-0.03-0.23-0.33--
Free Cash Flow
3.253.25-2.17-1.72-5.13-28.82
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Gross Margin
63.95%63.95%69.04%75.26%70.77%52.02%
Operating Margin
-14.44%-14.44%3.82%0.87%-7.05%-39.42%
Pretax Margin
-24.72%-24.72%-20.71%-15.92%-9.88%-112.64%
Profit Margin
-24.76%-24.76%-20.43%-24.31%-23.11%-112.53%
FCF Margin
5.65%5.65%-3.26%-2.63%-6.95%-29.82%

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingOct '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Forward PE
-9.039.03---
P/FCF Ratio
6.777.10----
PS Ratio
0.380.400.300.270.120.28